1 Division of
Hematology, Department of Medical Oncology, National Center for Cancer
Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha,
2 Department of Laboratory Medicine and Pathology, National Centre for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
3 Department of Laboratory Medicine and Pathology, Weill Cornell Medical College (WCMC-Q), Doha, Qatar.
4 Clinical pathology department, National Cancer Institute, Cairo-Egypt
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To the editor,
1. Chest x-ray for case (2) showing diffuse bilateral lung infiltrates.
|Figure 2. A graph showing base line serum level of Interleukin 6 and the effect of Tocilizumab (A) and the effect of Tocilizumab and Dexamethazone on Free light chain level (B).|
|Table 1. Clinicopathological characteristics, treatment and disease course for six patients with Multiple Myeloma and COVID-19 infection.|
|Table 2. Hematologic and biochemical characteristics of six patients with Multiple Myeloma and COVID-19 infection.|